What the two teams actually need to exchange
A useful handover is not a folder of scans. It is a short, structured message that lets the receiving clinician understand what has already been given, what is planned next, and what decision the patient is trying to make. For chemotherapy, that means the confirmed diagnosis and stage, the pathology and molecular reports that guided treatment, the names and dates of previous regimens, the reason each was stopped or changed, the most recent blood counts and organ-function results, and any dose reductions or delays.
The home team also needs something from China. If a Chinese hospital proposes a regimen, your home oncologist needs to see the drug names, the intended schedule, the monitoring plan and the criteria that would trigger a change. Without that, the home team cannot comment on whether the proposal fits your previous treatment or whether it duplicates or conflicts with something already tried.
The practical rule is symmetry. Whatever question you send to China should also be sent to your home team, and whatever answer China gives should be shared back. This avoids a situation where one side is working from an old summary and the other from a newer one.
Ask whether the review is for a new regimen or ongoing treatment
This is the first question to settle, because it changes what records matter and what the China team can realistically comment on. If you are seeking a review of a new regimen, the China clinician needs the full treatment history and the reason the current approach is being reconsidered. If you are asking about continuing treatment already underway, the focus shifts to cycle timing, monitoring results and how a temporary stay in China would fit around your existing schedule.
The distinction also affects what your home team must authorize. Continuing an existing regimen in another country involves questions about who writes the prescription, who reviews the blood counts, and who decides whether a cycle is delayed. Starting a new regimen involves a fresh assessment of suitability, alternatives and risks. Neither is a decision that can be made from records alone, and neither should be presented as already agreed.
Write the question in one sentence and put it at the top of the summary you send. For example: "Is the purpose of this review to consider a new regimen, or to plan monitoring around an existing one?" A clear answer tells you which documents to gather next.
How cycles and monitoring would be coordinated
Chemotherapy schedules differ according to the prescribed regimen, so the cycle length, rest period and monitoring intervals are specific to your treatment. Ask both teams to state, in writing, how they expect cycles to be timed if you travel, who will review blood counts between cycles, and what would happen if a result falls outside the expected range.
There is no single China-wide rule for this. Some hospitals may accept a shared-care arrangement; others may expect to manage the whole cycle locally. The only reliable answer comes from the named hospital and your home clinician. Ask the China hospital whether it can work from your home team's monitoring results, and ask your home team whether it is willing to review results generated in China. If either side is unsure, that is useful information before you book anything.
Do not treat a preliminary reply as confirmation. A message that says "we can discuss" is not the same as an agreed plan with dates, responsibilities and a named contact on each side. Ask what would need to be confirmed before a cycle could start, and who confirms it.
The exact missing record that blocks a useful answer
When a review stalls, it is often because one specific document is missing rather than because the whole file is incomplete. Common blockers include the original pathology report rather than a summary letter, the molecular or biomarker results that determined the current regimen, a medication list with dates and doses, or the most recent imaging compared with an earlier scan.
Ask the China team to name the single document that would most change their assessment. Then ask your home team whether that document can be released, and in what format. A short list of two or three specific items is easier for a busy clinic to act on than a request for "all records."
If a record genuinely cannot be obtained, say so explicitly in the summary. A clinician who knows a report is unavailable can explain the limits of the assessment. A clinician who assumes the file is complete may give an answer that does not apply to your situation.
Who is responsible for what after a plan is proposed
Once a China hospital proposes a regimen or a monitoring plan, responsibility needs to be explicit. Ask who will prescribe, who will review results, who decides on dose adjustments, and who the patient contacts between cycles. Ask the same of your home team. If the answers overlap or leave a gap, resolve that before treatment starts.
This matters most for ongoing treatment. If your home oncologist remains the prescriber, the China hospital's role may be limited to monitoring and supportive care. If the China hospital takes over prescribing, your home team needs to know so it does not issue conflicting instructions. Neither arrangement is automatically right; it depends on the regimen, the monitoring required and what each clinician is willing to accept.
A handover also has a time dimension. Ask each side how quickly it can respond to a question between cycles, and who covers when the usual clinician is away. A plan that depends on one person being reachable every day is fragile. Ask for a named alternative contact on each side, and confirm that the alternative has access to the same summary.
Put the agreed responsibilities in writing and share the same version with both teams. A one-page summary with names, roles and contact points prevents most misunderstandings. Update it whenever a cycle is completed, a dose is changed or a new result arrives, and send the updated version to both teams at the same time so neither is working from a stale copy.
If the two teams disagree about who should prescribe or monitor, that disagreement is itself the decision point. Do not start a cycle while it is unresolved. Ask each clinician to state in writing what they are willing to do and what they need from the other side, then send both statements to both teams. A written exchange of positions is more useful than a verbal summary passed through the patient, because it removes ambiguity about who said what.
The same discipline applies to results. When a blood count or scan is done, ask where the original report will be filed and who will read it first. If the China hospital reads it, your home team should receive the same report, not a paraphrase. If your home team reads it, the China hospital should receive the same version before the next cycle is planned. Sharing the original document, not a summary, prevents two clinicians from acting on different numbers.
None of this requires a single perfect system. It requires that both teams see the same question, the same records and the same division of responsibility before treatment continues. Where that is not yet true, the next step is to fix the exchange, not to book travel.
What to send first, and what to ask next
Start with a short summary rather than a complete archive. Include the diagnosis, the treatment history in chronological order, the current question and the name of your home oncologist. This is enough for an initial review and avoids sending sensitive documents before a receiving clinician has agreed to look at them.
Then ask two questions: whether the China team is reviewing a new regimen or ongoing treatment, and how cycles and monitoring would be coordinated if you travelled. The answers determine whether a fuller records exchange is worthwhile and what your home team needs to provide.
ChinaSpecialistCare can help with records organization, interpretation and specialist appointment requests for chemotherapy planning. An initial enquiry is free and does not require buying a proxy consultation. The hospital decides suitability, and no review confirms that treatment is available or that travel is appropriate. If your symptoms worsen, seek local care first rather than waiting for an overseas reply.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.